Unique ID issued by UMIN | UMIN000005503 |
---|---|
Receipt number | R000006524 |
Scientific Title | First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene -Phase II trial- |
Date of disclosure of the study information | 2011/05/01 |
Last modified on | 2017/08/13 09:01:05 |
First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene
-Phase II trial-
Phase II trial of CBDCA + S-1 + Gefitinib
First-line trial of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene
-Phase II trial-
Phase II trial of CBDCA + S-1 + Gefitinib
Japan |
non small cell lung cancer
Pneumology |
Malignancy
NO
to investigate the efficacy of CBDCA + S-1 + Gefitinib for patients with advanced or reccurent NSCLC patients harboring activating mutation of the EGFR gene
Efficacy
Exploratory
Explanatory
Phase II
The rate of one year progression free survival (1 year PFS rate)
response rate
progression free survival (PFS)
overall survival (OS)
safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
CBDCA + S1 + Gefitinib
20 | years-old | <= |
Not applicable |
Male and Female
1) diagnosis of NSCLC
2) advanced (stage IIIB who can not treat radiation therapy, and stage IV) or reccurent NSCLC patients
3) the patients who have the target region for RECIST v1.1
4) harboring activating mutation of EGFR gene (exon 19 delation, and L858R)
5) non perior chemotherapy, or 1 year or more after adjuvant chemotherapy
6) 20 years old or more
7) PS 0-1
8) good condition of main organ
9) over 12 weeks of lifetime expectancy
10) agreement of informed concent for this trial
1) the patients who have interstitial change.
2) allergy of the medication
3) double cancer
4) un-controled pleural effusion and ascites
5) severe conplications, including AMI, un-controled angina pectoris, and un-controled diabetis and hypertension
6) synptomatic brain metastasis
7) radiation therapy which has thoracic field
8) the patients who treat with flucytosine
9) the case of pregnancy and lactation
10) the doctors' jundgement of expurgate
28
1st name | |
Middle name | |
Last name | Shinji Atagi |
National hospital organization Kinki-Chuo Chest Medical Center
thoracic oncology
1180, nagasone-cho, kita-ku, sakai-city, osaka
072-252-3021
s-atagi@kch.hosp.go.jp
1st name | |
Middle name | |
Last name | Akihiro Tamiya |
National hospital organization Kinki-Chuo Chest Medical Center
thoracic oncology
1180, nagasone-cho, kita-ku, sakai-city, osaka
072-252-3021
atamiya@kch.hosp.go.jp
National hospital organization Kinki-Chuo Chest Medical Center
none
Self funding
osaka prefectual medical center for respiratory and allergic diseases
NO
2011 | Year | 05 | Month | 01 | Day |
Partially published
Main results already published
2011 | Year | 04 | Month | 19 | Day |
2011 | Year | 05 | Month | 01 | Day |
2014 | Year | 04 | Month | 01 | Day |
2017 | Year | 03 | Month | 31 | Day |
2011 | Year | 04 | Month | 25 | Day |
2017 | Year | 08 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006524
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |